摘要
目的探讨氯咪帕明合并碳酸锂治疗双相抑郁的疗效及安全性。方法将71例符合CCMD-3诊断标准的双相抑郁患者随机分为两组,分别给予氯咪帕明单用及合并碳酸锂治疗,共治疗6周。采用HAMD评定疗效,TESS评定副反应。结果单用组有效率54.5%,合用组有效率78.9%,差异有显著性。转躁率单用组36%,合用组16%,两者比较有显著性差异。结论合用组疗效肯定,转躁率低。
Objective To explore the efficacy and side effects of chlomipramine with lithium in the treatment of bipolar depression. Methods A total of 71 patients who met the criteria of CCMD-3 for bipolar depression were randomly assigned into two groups, one group treated with chlompramine combined with lithium, the other with chlomipramine alone for 6 weeks. The efficacy was assessed by Hamilton Depression rating scale （HAMD） ,and the safety was assessed by Treatment Emergent Symptom Scale （TESS）. Results The improvement rate in the study group was 78.9%, and that in the control group was 54.5%, and there was significant difference between two groups. The incidences of depression shifted to mania episode in study group and control group were 16% and 36%, and singnificant difference existed. Conclusion Chlomipramine combined with lithium is effective with lower incidence of shifted to mania episode.
出处
《山东精神医学》
2005年第4期248-249,共2页
Shangdong Archives of Psychiatry
关键词
氯咪帕明
碳酸锂
双相抑郁
Chlomipramine Lithium Bipolar depression
